Skip to main content
Sailong Pharmaceutical Group Co., Ltd. logo

Sailong Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 002898 ISIN · CNE1000032S5 LEI · 8368004F5Y6BSB6US681 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,117 across all filing types
Latest filing 2021-01-07 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002898

About Sailong Pharmaceutical Group Co., Ltd.

https://www.sailong.cn

Sailong Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and marketing of high-end generic drugs and innovative formulations. The company maintains an integrated industrial chain encompassing active pharmaceutical ingredients (APIs) and finished dosage forms. Its product portfolio primarily targets therapeutic areas such as cardiovascular and cerebrovascular diseases, the digestive system, and anti-infective treatments. Key products include Monosialotetrahexosylganglioside Sodium Injection and Pantoprazole Sodium for Injection. The group emphasizes technological innovation and quality control to provide clinical solutions for complex medical conditions.

Recent filings

Filing Released Lang Actions
关于子公司获得注射用艾司奥美拉唑钠药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Zhuhai Sailong Pharmaceutical Co., Ltd. regarding its subsidiary obtaining a drug registration certificate for an injectable drug. It includes details about the drug, regulatory approval, and risk warnings. The document is short (1109 characters) and serves as an official announcement of a regulatory approval event rather than a financial report or detailed management discussion. It does not contain financial data, earnings, or management changes. It is not a report but an announcement of a regulatory milestone. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-01-07 Chinese
第二届董事会第三十次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions from the 30th meeting of the 2nd Board of Directors of Zhuhai Sailong Pharmaceutical Co., Ltd. It details the meeting's convening, attendance, agenda items, voting results, and references to related independent director opinions. There is no financial data or report content, only a formal disclosure of board decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2021-01-03 Chinese
独立董事关于第二届董事会第三十次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from independent directors regarding a specific board meeting agenda item about a bank credit application and guarantee by the actual controller. It references regulatory guidelines and governance rules but does not contain financial statements or detailed financial data. The document is short (901 characters) and serves as a formal opinion or certification related to board decisions rather than a full report or announcement of voting results. It is not an Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement since it contains substantive content (independent opinion). It is best classified under Board/Management Information (MANG) as it relates to board meeting matters and independent directors' opinions on governance issues.
2021-01-03 Chinese
关于向银行申请授信并由实际控制人提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhuhai Sailong Pharmaceutical Co., Ltd. regarding the company's application for bank credit and the provision of guarantees by the actual controllers. It details the credit amount, terms, related party information, board meeting approvals, and independent directors' opinions. The document is relatively short (1946 characters) and focuses on a financing update rather than a full financial report. There are no financial statements or comprehensive financial data included. The content fits the description of a Capital/Financing Update (CAP) as it provides information on financing activities and credit arrangements.
2021-01-03 Chinese
独立董事关于第二届董事会第三十次会议相关事项的事前认可意见
Regulatory Filings Classification · 95% confidence The document is a statement from independent directors providing prior approval opinions related to a board meeting agenda item about applying for bank credit with guarantees from actual controllers. It references regulatory guidelines and company articles but does not contain financial statements, audit results, or detailed financial data. The document is short (896 characters) and serves as a formal opinion or certification related to board matters, specifically about a financing guarantee. It is not a full report, earnings release, or audit report. It is also not a management change announcement or voting result. The content aligns best with a Regulatory Filing (RNS) as it is a compliance-related document that does not fit other specific categories.
2021-01-03 Chinese
关于股价异动的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Zhuhai Sailong Pharmaceutical Co., Ltd. regarding abnormal stock price fluctuations over several trading days. It includes the company's investigation and confirmation that no undisclosed material information exists that could have caused the price movement. The document is short (1214 characters) and serves as a regulatory disclosure about stock price anomalies and compliance with disclosure rules. It does not contain financial statements, earnings data, or detailed reports. It is not an annual or interim report, earnings release, or management discussion. It is a regulatory announcement about stock price abnormality and information disclosure compliance, fitting the category of Regulatory Filings (RNS).
2020-12-29 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.